LINK BETWEEN LEVELS OF EXTRACELLULAR VESICLES OR EVS IN THE BLOOD AND TISSUE DAMAGE CAUSED BY DISEASES Cellular couriers: Body’s ‘delivery trucks’ could lead to new cancer blood test
With
Dr Georgia Atkin-Smith, Senior Postdoctoral researcher and NHMRC Investigator Grant Research Fellow, WEHI, Melbourne, Australia
Associate Professor Edwin Hawkins, Laboratory Head, WEHI, Melbourne, Australia
CASE STUDY
Filmed in Melbourne | March 2025
A landmark study led by WEHI and La Trobe University has found a potential new diagnostic marker that could be used to better detect the level of tissue damage in our bodies.
This study revealed, for the first time, a link between levels of EVs in the blood and tissue damage caused by diseases such as leukaemia.
Researchers hope to leverage the critical new insight to develop a blood test to monitor cancer patients with tissue damage, which could, in future, enhance treatment strategies for blood cancers and other diseases.
Extracellular vesicles (EVs) are like small delivery trucks in the human body that are dispatched by our cells to distribute important materials like proteins, fats and genetic information to other cells.
This delivery system helps cells communicate with each other, especially when they are under stress or dying.
Research into how EVs form and their link to disease progression is challenging because of their small size, with most studies restricted to a ‘cells-in-a-dish’ approach.
In an unprecedented study, researchers were able to overcome this significant barrier by imaging live EVs inside the bone marrow of mice.
The study involved a significant collaboration with Professor Ivan Poon, Director of the La Trobe Research Centre for Extracellular Vesicles (RCEV) – the largest group of EV researchers in the Southern Hemisphere.
The WEHI research team is now assessing whether EVs can be used as a biomarker in acute myeloid leukemia (AML) patients. They hope to develop new tools and techniques that would allow clinicians to determine the impact of disease on healthy tissue, and assess the disease progression by analysing patient samples.
The study, published in Nature Communications Oct 2024, also involved collaborations with the University of Melbourne, The Florey, Olivia Newton-John Cancer Research Institute, Peter MacCallum Cancer Centre and Monash University.
The research was supported by the National Health and Medical Research Council, Australian Research Council, CASS Foundation, Jack Brockhoff Foundation, L’Oreal UNESCO For Women in Science, Victorian Cancer Agency, a Sir Clive McPherson Family Fellowship and a Rae Foundation grant.
Source: WEHI News
-
Life-changing donor milk for preterm babies
Dr Laura Klein is National Milk Research Leader at Australian Red Cross Lifeblood. Australian Red Cross Lifeblood is funded by Australian governments to provide life-giving blood, plasma, and transplantation and biological products.
Dr Klein works with clinicians and researchers across Australia to understand how donated breast milk can be used to improve outcomes for vulnerable babies. She’s passionate about generating evidence to improve the products and services that milk banks provide to donors and the families who receive donated breast milk.
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
-
Therapies for chronic myeloid leukaemia
Professor Tim Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times.
